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Murine ES cells (129 CCE) obtained from Dr. Nagy laboratory,
Canada, were subjected to the in vitro primary hematopoietic
differentiation media containing methylcellulose, IMDM, IL -3,
IL-6, and SCF (stem cell factor) without LIF (leukemia inhibitory
factor) to promote embryoid body (EB) formation. Total RNA was
collected on day 3, 5, and 9 EBs for gene expression studies using
RT-PCR. On day 9, EBs were subjected to secondary differenti-
ation using three different cytokines and growth factors combina-
tion, (1) SCF, EPO, dexamethasone, IGF, (2) SCF, IL-3, IL-6,
TPO, (3) SCF IL-3, IL-6, TPO, EPO. Total RNA from day12 of
secondary differentiated ES cells was collected to study cytokines
and growth factors dependent erythrocytic differentiation and gene
regulation, using RT-PCR. Our results demonstrate upregulation
of Gata-1, Flk-1, HoxB-4, Epo-R, and globin genes (
-globin,
BH-1 globin, b-major globin, e-globin, and z-globin) in the 9 days
old EBs, whereas RNA collected from 5 days old EBs showed
expression of HoxB-4, e-globin, -globin, BH1-globin, and
FLK-1. Three days old EBs showed only HoxB-4 and FLK-1 gene
expression and lack of expression of globin genes, indicating that
erythropoiesis-speciﬁc genes and hemoglobin switch activate later.
Gene expression studies of RNA collected from secondary differ-
entiated ES cells and media containing dexamethasone showed
downregulation of GATA-3 and upregulation of GATA-1, Flk-1,
and Epo-R in comparison to the two other cytokines and growth
factors media combination. These results conﬁrm our hypothesis
that dexamethasome induces erythropoiesis by downregulating
GATA 3 and upregulating erythropoietic genes such as
GATA-1, Flk-1, and Epo-R. The morphological characteristics of
cells after secondary differentiation showed enhanced production
of erythrocytic precursors in dexamethasone containing media,
which corresponded with molecular studies.
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SHORT TERM AND PROLONGED EFFECTS OF IRRADIATION ON HUMAN
MESENCHYMAL STEM CELLS
Li, J.1, Kwong, D.L.W.2, Chan, G.C.F.1 1. Department of Paediatrics
& Adolescent Medicine, The University of Hong Kong, HKSAR, China;
2. Department of Clinical Oncology, The University of Hong Kong,
HKSAR, China.
Background: Mesenchymal stem cells (MSCs) are important com-
ponent of the bone marrow microenvironment and are progenitors of
mesenchymal tissues. The effect of therapeutic irradiation to MSCs
remains unexplored. Materials and Methods: MSCs were derived
from healthy donors. Effects of irradiation with single dose (dosage
ranges 2, 4, 6, 8, 12 Gy) on human MSCs were investigated. Post-
irradiation cell proliferation was assessed by XTT assay and cell
counting. Osteogenic and adipogenic differentiation function were
evaluated after irradiation. ALP activity and calcium deposition in
irradiated MSCs were quantiﬁed following osteogenic induction. Re-
sults: Irradiation inhibited proliferation of human MSCs up to 2
weeks post-irradiation but thereafter, survival cells regained normal
proliferation rate back to the control level. ALP activity and calcium
deposition were both reduced in a dose-dependant fashion. Maximum
reduction (16% of control ALP activity and 9% of control calcium
level) was noted in MSCs under 12 Gy irradiation. Adipocyte per-
centage was reduced by 50% in cultures that received irradiation 	4
Gy. Attempts to protect the irradiated cells with 1 M all-trans
retinoic acid showed no protective effect on MSCs proliferation and
differentiation. Conclusion: Irradiation damaged the capacity of hu-
man MSCs proliferation and differentiation. However, full recovery
of growth and renewal ability was observed in surviving MSCs after 2
weeks.
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CORD BLOOD EXPANSION WITH SELECTIVE DEPLETION OF CD52
POSITIVE CELLS USING CAMPATH-1H: INCREASED CD34 CELLS AND
MEGAKARYOCYTIC PROGENITORS
Lim, C.K.1, Sun, L.1, Chua, W.T.2, Lim, S.N.2, Hwang, W.Y.K.1,3 1.
Singapore General Hospital, Singapore, Singapore; 2. Ngee Ann Poly-
technic, Singapore, Singapore; 3. Singapore Cord Blood Bank, Singapore,
Singapore.
The overgrowth of mature haematopoietic cells leads to a reduc-
tion of the long term proliferative potential of cord blood expan-
sion cultures. We postulated that the depletion of CD52 positive
cells in these cultures could lead to a higher percentage of imma-
ture progenitors including CD34 positive cells and megakaryocyte
progenitors. Immunomagnetic isolation of CD34 cells was per-
formed on leukocyte enriched cord blood samples, followed by
culture in SFEM serum free medium in the presence of 50 mg/ml
of: stem cell factor (SCF); Flt3-ligand and thrombopoietin (Tpo)
for up to 14 days. Well-demarcated populations of CD52 and
CD34 positive cells were found on ﬂow cytometric analysis. Phar-
maceutical-grade humanized anti-CD52 monoclonal antibody
Campath-1H was used, in the presence of complement, to deplete
CD52 positive cells during the cord blood expansion cultures.
Addition of the antibody resulted in a signiﬁcant reduction of
CD52 positive cells in the cord blood cultures versus cells grown in
culture without anti-CD52 antibodies (CD52 cells 0.64% with
Campath-1H versus 13.76% in cultures without the antibody
added). The percentage of CD34 positive cells (7.13% with Cam-
path-1H versus 1.04% in cultures without antibody) and
megakaryocyte progenitors after 3 weeks of cultures were also
higher in Campath-1H treated cord blood cultures. The differ-
ences were more pronounced when Interleukin-3 (IL3) was added
to the cytokine cocktail for cord blood expansion. We conclude
that anti-CD52 antibodies may be used to deplete mature cells
from cord blood cultures resulting in a signiﬁcantly higher per-
centage of immature CD34 positive cells and megakaryocytic pro-
genitors.
LATE EFFECTS/QUALITY OF LIFE
310
MEASUREMENT OF MORTALITY IN LONG-TERM HEMOPOIETIC STEM
CELL TRANSPLANT SURVIVORS
Nivison-Smith, I.1, Bradstock, K.F.2, Dodds, A.J.3, Ma, D.D.F.3,
Szer, J.4 1. Australasian Bone Marrow Transplant Recipient Registry
(ABMTRR), Darlinghurst, NSW, Australia; 2. Westmead Hospital,
Westmead, NSW, Australia; 3. St Vincent’s Hospital, Darlinghurst,
NSW, Australia; 4. Royal Melbourne Hospital, Parkville, Victoria,
Australia.
Aim: To measure mortality rates in long-term hemopoietic stem
cell transplant survivors and compare these with the general pop-
ulation. Method: Records of patients who had survived more than
2 years post autologous or allogeneic stem cell transplant were
drawn from the ABMTRR database. Annual mortality was calcu-
lated for this group and compared to the mortality of the Australian
population using indirect age-standardized mortality rates. Re-
sults: Among 1502 allogeneic recipients disease free at 2 years,
there were 36 deaths (18 from non-malignancy related causes) in
the third year compared to an expected 3. Among 778 allogeneic
recipients disease free at 5 years, there were 3 deaths in the sixth
year deaths (2 from non-malignancy related causes) compared to
an expected 1. In contrast, among 2741 autologous recipients
disease free at 2 years, there were 52 deaths (8 from non-malig-
nancy related causes) in the third year compared to an expected 9.
Among 1188 autologous recipients disease free at 5 years, there
were 14 deaths in the sixth year (6 non-malignancy) compared to
an expected 3.Conclusion:The non-malignancy mortality of both
allogeneic and autologous HSCT recipients approaches population
norms for those who survive more than 5 years post transplant.
Indirect age-standardized mortality calculations offer a relatively
straightforward mortality analysis strategy. The ABMTRR is an
important national data resource providing timely information on
transplant activity and outcome across Australia and New Zealand.
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LONG-TERM OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANT:
SINGLE INSTITUTION EXPERIENCE OF A LARGE COHORT
Abou Mourad, Y.R.1, Lau, B.C.Y.2, Barnett, M.J.1, Forrest, D.L.1,
Hogge, D.E.1, Nantel, S.H.1, Nevill, T.J.1, Shepherd, J.D.1,
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Lavoie, J.C.1 1. Leukemia/BMT Program of BC, Vancouver General
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Background and Methods: We analyzed the late outcome of
long-term survivors of allogeneic stem cell transplantation (allo-
SCT) treated by the Leukemia/Bone Marrow Transplant Program
of British Columbia. Results: We reviewed the charts of 430
patients (pts) who received allo-SCT between 1981 and 2002 for
hematologic malignancies and who were free of their primary
disease for at least two years after transplant. Late recurrent pri-
mary malignancy was found in 13% (57 pts) of allo-SCT recipients
and was the primary cause of late death. 31 (7%) allo-SCT recip-
ients died of non-relapse causes at a median of 5.5 year (range 2 to
15.6) post allo-SCT. Non relapse causes of death were GVHD (11
pts), second cancer (8), coronary disease (3), infection (2), miscel-
laneous (5), and unknown (2). 342 non relapse long-term allo-SCT
survivors were evaluated for late complications. Median follow-up
for the survivors was 8 (range 2 to 23) years. Chronic graft versus
host disease (cGVHD) was diagnosed in 205 (60%) survivors with
more than 50% of pts still having symptoms of cGVHD at last
follow-up. Cardiovascular complications in survivors included hy-
pertension (21%), coronary disease (3%) and myocardial infarction
(2%). Renal failure was diagnosed in 64 (17%) survivors; it resolved
over time in 17 pts; 6 pts needed dialysis. Endocrine complications
seen in survivors included dyslipidemia (10%), hypothyroidism
(9%), diabetes (7%), osteopenia/osteoporosis (25%), hypogonad-
ism in females (76%) and hypogonadism in males (7%). Depres-
sion was reported in 41 (11%) survivors, and 2 pts attempted
suicide. Cognitive impairment and other psychiatric problems
were identiﬁed in 2% and 3% respectively. Sexual dysfunction was
reported in 6% of survivors. Conclusions: In patients who receive
allo-SCT as treatment for hematologic malignancy and who are
disease-free 2 years post transplant, probability of durable remis-
sion is high with acceptable but deﬁnite late toxicity. The occur-
rence of late events necessitates lifelong medical surveillance.
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SECOND SOLID CANCERS AFTER ALLOGENEIC STEM CELL TRANSPLAN-
TATION: THE VANCOUVER EXPERIENCE
Gallagher, G.1, Hogge, D.E.1, Nevill, T.J.1, Nantel, S.H.1,
Barnett, M.J.1, Shepherd, J.D.1, Sutherland, H.J.1, Toze, C.L.1,
Smith, C.A.1, Lavoie, J.C.1, Song, K.W.1, Forrest, D.L.1 Leukemia/
BMT Program of British Columbia, Vancouver General Hospital, Van-
couver, BC, Canada.
The development of second solid cancers in recipients of hema-
topoietic stem cell transplants (SCT) represents a serious compli-
cation among long term survivors. To assess the incidence and
associated risk factors for second solid cancers following allogeneic
SCT, we performed a retrospective analysis of 926 consecutive
patients (pts) who underwent an allogeneic SCT between January
1985 and December 2003. Primary diagnoses were AML (235),
ALL (103), CML (216), lymphoproliferative disorders (150), MDS
(96), MM (80), or other (46). Median age at SCT was 39 years
(range 12–65) and median time from diagnosis to SCT was 5.1
months (range 0.2–345). Six hundred forty pts had a sibling donor
and 286 had an unrelated donor. Stem cell source was bone mar-
row (810), peripheral blood (109), or both (7). Conditioning reg-
imens were: TBI-based (488), BuCy other (414), other (24). The
graft was T cell depleted in 43 pts. With a median follow-up of
22.2 months post SCT (range 0.07–230.5) for all 926 pts and 84.2
months (range 8.4–230.5) for surviving pts, 30 solid malignancies
have occurred in 28 pts at a median of 81.4 months post SCT
(range 1.4–207.5). These second tumors involved skin (8 basal cell
carcinoma, 4 invasive squamous cell carcinoma), lung (5), oral
cavity (4), colon (2), bladder (2) breast (1), kidney (1), parotid gland
(1), vulva-in situ (1), and primary unknown (1). Of the 28 pts, 6
died from the second cancer at a median of 6.1 months (range
0.9–36) following the diagnosis. The 10-year cumulative incidence
of all second solid cancers was 3.1% (95% CI 2–5%). Compared to
age and gender adjusted cancer rates in the general population of
BC, the relative risk (RR) of developing a second solid cancer after
allografting excluding nonmelanoma skin cancer was 1.85 (95% CI
1.04–3.06), P  .019. In multivariate analysis, signiﬁcant risk
factors were recipient age at SCT 	 40 years (RR 4.8), P .01 and
donor gender [female donor/male recipient (RR 5.4), female do-
nor/female recipient (RR 2.3)] P .002. We conclude that alloge-
neic SCT recipients are at an increased risk of developing a second
solid cancer compared to the general population, particularly if the
recipient is 	40 years old at the time of allografting. It is also
apparent that male recipients of a female graft have a higher risk of
second solid cancers. Longer follow-up is needed to more fully
assess the incidence and risk factors for second solid tumors post-
transplant due to their long latency period.
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ASSESMENT OF BONE LOSS AFTER BONE MARROW TRANSPLANTA-
TION IN PATIENTS WITH LEUKEMIA AND LYMPHOMA
Esfahani, A.1, Iravani, M.1, Khoushniat, M.2, Ghoreishi, Z.1,
Shamshiri, A.1, Ghavamzadeh, A.1 1. Hematology-Oncology and BMT
Research Center, Tehran University of Medical Sciences, Tehran, Islamic
Republic of Iran; 2. Endocrinology & Metabloism Resarch Center, Teh-
ran University of Medical Sciences, Tehran, Islamic Republic of Iran.
Bone marrow transplantation (BMT) is the treatment of choice
for many patients with malignant and non-malignant diseases. As
the survival of these patients increases, long term complications
such as osteoporosis should be considered, because it associates
with morbidity and mortality of the patients directly. We have
prospectively investigated 63 patients undergoing BMT for acute
and chronic leukemia and lymphoma. Bone mineral density (BMD)
was measured with dual X-ray absorptiometry before BMT, 6 and
12 months later also. Osteocalsin and bone alkaline phosphatase as
markers of bone formation and c-terminal telopeptides of type 1
collagen as a marker of bone resorption were assessed. Moreover,
serum concentration of calcium, phosphorous, vitamin D, PTH,
and sex hormones (FSH, LH, testostorone, estradiol) were mea-
sured. There was signiﬁcant decrease in BMD of femoral neck 6
months after BMT (0.06 gr/cm2 in allogenic and 0.04 gr/cm2 in
autologous) but no considerable changes were seen in lumbar
vertebrae. Also, more decrease in bone loss between sixth and
twelfth months was not observed. After one year the rate of os-
teopenia and osteoporosis increased in allogenic and autologous
BMT 10% and 20%, respectively. There was signiﬁcant increase in
the marker of bone resorption but bone formation markers not
only decreased but also increased at the same time. No distinct
difference was observed in serum biochemical turnover markers
between males and females, or between autologous and allogenic
BMT patients. Seventy-six and 90% of the women went into
menopausal state in 6 and 12 months after BMT, respectively, but
male sex hormones did not change considerably. In conclusion, the
risk of bone loss in both allogenic and autologous BMT is higher
in femoral neck rather than lumbar vertebrae and it occurred
mainly in the ﬁrst 6 months after BMT. Preventional and clinical
procedures should be considered.
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SPECIES-SPECIFIC DIAGNOSIS OF ASPERGILLUS INFECTIONS IN HSCT
PATIENTS
Reddy, S.1, Grantham, K.1, Nath, R.2, Dalal, J.3, Manna, P.1 1.
ViraCor Laboratories, Lee’s Summit, MO; 2. St Joseph’s Regional
Medical Center, Patterson, NJ; 3. Children’s Mercy Hospital, Kansas
City, MO.
Introduction: Despite recent advances in diagnosis and treat-
ment, invasive Aspergillosis (IA) remains a signiﬁcant threat to
hematopoietic stem cell transplant (HSCT) patients. It is estimated
that over 90% of undiagnosed and untreated cases of IA result in
death. Because anti-fungal drug susceptibility varies between the
Aspergillus species, species-speciﬁc identiﬁcation improves the IA
disease management signiﬁcantly. Recently, real time PCR assays
have been reported in diagnosing IA, however, these assays lack
speciﬁcity. Using scorpion technology, we developed a rapid, sen-
sitive, and quantitative real time PCR assay for species-speciﬁc
identiﬁcation of Aspergillus infections that does not cross-react with
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